Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 1, 2026, 9:30 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 43 matching trials from the live ClinicalTrials.gov search.
Conditions
Migraine With Aura, Migraine Without Aura
Interventions
Dronabinol MDI
Drug
Lead sponsor
Solvay Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
29
States / cities
Huntsville, Alabama • Tucson, Arizona • Anaheim, California + 23 more
Conditions
Migraine
Interventions
DFN-15 Dose A (treatment A), DFN-15 Dose B (treatment B), Placebo (treatment C)
Drug · Other
Lead sponsor
Dr. Reddy's Laboratories Limited
Industry
Eligibility
18 Years to 65 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
6
States / cities
Long Beach, California • Santa Monica, California • Watertown, Massachusetts + 3 more
Conditions
Migraine Disorders
Interventions
Placebo, Combination Product (sumatriptan succinate/naproxen sodium)
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
169 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
28
States / cities
Jasper, Alabama • Oceanside, California • San Francisco, California + 25 more
Conditions
Pediatric Migraine
Interventions
Rimegepant/BHV3000, Matching placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
6 Years to 17 Years
Enrollment
2,100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
169
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Tempe, Arizona + 107 more
Conditions
Migraine
Interventions
EVO756, Dose 1, EVO756, Dose 2, Placebo
Drug
Lead sponsor
Evommune, Inc.
Industry
Eligibility
18 Years to 64 Years
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
26
States / cities
Chandler, Arizona • Buena Park, California • Fresno, California + 21 more
Conditions
Migraine With or Without Aura
Interventions
Naltrexone and Acetaminophen, Naltrexone and Acetaminophen-High Dose, Naltrexone Alone (regular dose), Acetaminophen Alone, Matching Placebo
Drug
Lead sponsor
Allodynic Therapeutics, Inc
Industry
Eligibility
18 Years and older
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
North Miami, Florida
Conditions
Migraine
Interventions
Diclofenac Potassium for Oral Solution
Drug
Lead sponsor
Depomed
Industry
Eligibility
12 Years to 17 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
2
States / cities
Tampa, Florida • Amherst, New York
Completed Phase 3 Interventional Results available

Migraine Study in Adolescent Patients

NCT00843024
Conditions
Migraine Disorders
Interventions
Sumatriptan and Naproxen Sodium, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years to 17 Years
Enrollment
589 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
79
States / cities
Gilbert, Arizona • Litchfield Park, Arizona • Phoenix, Arizona + 71 more
Conditions
Migraine
Interventions
Ubrogepant
Drug
Lead sponsor
AbbVie
Industry
Eligibility
6 Years to 17 Years
Enrollment
1,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
109
States / cities
Huntsville, Alabama • Saraland, Alabama • Little Rock, Arkansas + 92 more
Conditions
Migraine Disorders
Interventions
sumatriptan and naproxen sodium combination tablet, sumatriptan tablet, naproxen sodium tablet
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
407 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
49
States / cities
Chandler, Arizona • Gilbert, Arizona • Litchfield Park, Arizona + 43 more
Conditions
Migraine, With or Without Aura
Interventions
Ubrogepant, Placebo-matching Ubrogepant, Usual Care
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 76 Years
Enrollment
1,254 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
177
States / cities
Birmingham, Alabama • Chandler, Arizona • Mesa, Arizona + 137 more
Conditions
Migraine
Interventions
Ubrogepant, Placebo-Matching Ubrogepant
Drug
Lead sponsor
AbbVie
Industry
Eligibility
6 Years to 17 Years
Enrollment
1,059 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
125
States / cities
Huntsville, Alabama • Saraland, Alabama • Phoenix, Arizona + 102 more
Conditions
Acute Migraine With or Without Aura
Interventions
sumatriptan nasal powder, Placebo
Drug
Lead sponsor
Currax Pharmaceuticals
Industry
Eligibility
12 Years to 17 Years
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
40
States / cities
Phoenix, Arizona • Anaheim, California • Los Angeles, California + 33 more
Completed Phase 3 Interventional Results available

Efficacy, Tolerability, and Safety of DFN-15

NCT03009019
Conditions
Migraine Headache
Interventions
DFN-15 Active, DFN-15 Placebo
Drug · Other
Lead sponsor
BioDelivery Sciences International
Industry
Eligibility
18 Years to 75 Years
Enrollment
631 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
43
States / cities
Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 39 more
Conditions
Acute Treatment of Migraine
Interventions
Rimegepant (PF-07899801)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
6 Years to 17 Years
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
115
States / cities
Scottsdale, Arizona • Tempe, Arizona • Anaheim, California + 77 more
Conditions
Migraine, Pain, Nausea, Vomiting, Aura
Interventions
Arm 1: CL-H1T, Arm 2: CL-H1T, Arm 3: Sumatriptan Succinate 100 mg capsule, Arm 4: Promethazine HCl 18.75 mg, Arm 5: Promethazine HCl 37.5 mg, Placebo
Drug · Other
Lead sponsor
Charleston Laboratories, Inc
Industry
Eligibility
18 Years to 75 Years
Enrollment
475 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
3
States / cities
New Port Richey, Florida • North Miami Beach, Florida • Greer, South Carolina
Conditions
Migraine, With or Without Aura
Interventions
Rimegepant, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
1,485 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
50
States / cities
Birmingham, Alabama • Gilbert, Arizona • Tempe, Arizona + 45 more
Conditions
Migraine
Interventions
MTX101, Placebo
Drug
Lead sponsor
Manistee Therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
7
States / cities
La Jolla, California • Santa Monica, California • Miami, Florida + 4 more
Conditions
Migraine, With or Without Aura
Interventions
Ubrogepant, Placebo-matching Ubrogepant
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 75 Years
Enrollment
1,686 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
109
States / cities
Birmingham, Alabama • Chandler, Arizona • Phoenix, Arizona + 91 more
Conditions
Episodic Migraine
Interventions
DFN-11, Placebo
Drug · Other
Lead sponsor
Dr. Reddy's Laboratories Limited
Industry
Eligibility
18 Years to 65 Years
Enrollment
268 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
16
States / cities
Santa Monica, California • Jacksonville, Florida • Maitland, Florida + 13 more
Conditions
Migraine, With or Without Aura
Interventions
Atogepant, Placebo-matching Atogepant
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 75 Years
Enrollment
834 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
75
States / cities
Birmingham, Alabama • Chandler, Arizona • Carlsbad, California + 66 more
Conditions
Migraine, Migraine With or Without Aura
Interventions
Meditation
Behavioral
Lead sponsor
Maharishi International University
Other
Eligibility
18 Years to 60 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Conditions
Migraine
Interventions
Galcanezumab
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
13
States / cities
Santa Monica, California • Spring Valley, California • Stamford, Connecticut + 10 more
Conditions
Migraine, Without Aura
Interventions
sumatriptan succinate / naproxen sodium, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
679 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
70
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Anaheim, California + 58 more